Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Conditions
- HIV Infections
- Registration Number
- NCT00038532
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (53)
Phoenix Body Positive, Inc.
🇺🇸Phoenix,, Arizona, United States
Paul J. Cimoch, M.D.
🇺🇸Fountain Valley, California, United States
AIDS Health Care Foundation - Research Center
🇺🇸Los Angeles, California, United States
Tower Infectious Diseases Medical Associates
🇺🇸Los Angeles, California, United States
20th Avenue Medical Center Kaiser Permanente
🇺🇸Denver, Colorado, United States
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
Associates in Research
🇺🇸Fort Myers, Florida, United States
Gary J. Richmond, M.D.
🇺🇸Ft. Lauderdale, Florida, United States
University of Miami School of Medicine
🇺🇸Miami, Florida, United States
Scroll for more (43 remaining)Phoenix Body Positive, Inc.🇺🇸Phoenix,, Arizona, United States